BioSpace News Archive

Business

Germany’s Novaliq Sets Up U.S. Subsidiary in Cambridge, Massachusetts

As an emerging leader in the field of ophthalmology, Novaliq is currently pursuing two late-stage clinical trials in the United States.

January 8, 2018
·
3 min read
Pharm Country

Celgene Corporation Announces Preliminary 2017 Unaudited Results and 2018 Financial Guidance

Celgene today provided a business update as well as its preliminary 2017 unaudited results and financial guidance for 2018 at the 36th Annual J.P. Morgan Healthcare Conference.

January 8, 2018
·
21 min read
Business

Gardner Denver Continues its Focus on Strategic Talent Deployment

Mr. Thikoll is an accomplished business leader whose career has spanned a number of leading industrial companies, including more than 15 years at Danaher Corporation in roles of increasing responsibility focused on operational excellence, lean manufacturing and the Danaher Business System.

January 8, 2018
·
5 min read
Business

Teneobio Announces a Strategic Alliance with TESARO to Develop the Next Generation of Immuno-Oncology, Multispecific Antibodies

TESARO will have exclusive licenses to the antibodies for clinical development and commercialization on a global basis.

January 8, 2018
·
2 min read
Business

Adaptimmune Announces Two Manufacturing Achievements on Its way to Become the First Fully Integrated TCR T-cell Therapy Company

In addition, Adaptimmune announced an agreement with Cell and Gene Therapy Catapult for vector production in the UK, which will ensure vector supply for its ongoing and future clinical studies.

January 8, 2018
·
4 min read
Business

REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy

AveXis’ initial proprietary gene therapy candidate, AVXS-101, is in a pivotal trial for the treatment of SMA Type 1, and a Phase 1 trial for SMA Type 2. AVXS-101 uses REGENXBIO’s NAV AAV9 vector.

January 8, 2018
·
9 min read
Policy

Athenex Announces Chinese FDA Allowance of Investigational New Drug Application of Oraxol to Begin Clinical Trials

Acceptance of the Oraxol IND by the Chinese FDA allows Athenex to commence a clinical trial program for Oraxol in China in 2018.

January 8, 2018
·
4 min read
Business

AMAG Pharmaceuticals Announces Preliminary 2017 Financial Results and Provides 2018 Guidance

A live audio webcast of the presentation and following breakout session will be accessible through the Investors section of AMAG’s website.

January 8, 2018
·
18 min read
NeuClone Discloses Details of its Fifth Product: a Biosimilar Candidate for Prolia/XGEVA (Denosumab)

NeuClone Pty. Ltd. today disclosed the fifth biosimilar candidate being developed in its pipeline of mAb products.

January 8, 2018
·
3 min read
BioForest

AGC Bioscience, Biomeva, and CMC Biologics to Provide Services Under the Brand AGC Biologics

AGC Biologics, a convergence of Asahi Glass Company Bioscience, Biomeva GmbH, and CMC Biologics , announced today that effective January 8, 2018, the company will be integrated and newly branded as AGC Biologics.

January 8, 2018
·
3 min read